Publicou 6 edições por ano
ISSN Imprimir: 1040-8401
ISSN On-line: 2162-6472
Indexed in
Targeting OX40 and OX40L for the Treatment of Autoimmunity and Cancer
RESUMO
The optimal activation of naïve T cells requires TCR−mediated recognition of cognate peptide−MHC complexes on antigen presenting cells in the presence of costimulatory signals. Although signals provided via CD28−B7 interactions are important for enhancing the initial T−cell response, other costimulatory signals are required for sustaining the response and promoting both T−cell differentiation and survival. In particular, engagement of OX40 (CD134) by its natural ligand OX40L (CD134L) or OX40 agonists has been shown to provide key signals that can augment CD4 and CD8 T−cell responses. Importantly, numerous studies have highlighted the ability of OX40−specific agonists or antagonists to enhance antitumor immunity or ameliorate autoimmune disease, respectively. On the basis of these studies, the development of OX40− and OX40L−specific reagents has been pursued for clinical use. Given the emerging role of OX40 and OX40L as novel therapeutic targets, this review will focus on the cellular and molecular mechanisms of OX40−mediated T−cell costimulation with a special emphasis on the role of OX40-OX40L interactions in the etiology and treatment of autoimmunity and cancer.
-
Lee Chern Siang, Cragg Mark, Glennie Martin, Johnson Peter, Novel antibodies targeting immune regulatory checkpoints for cancer therapy, British Journal of Clinical Pharmacology, 76, 2, 2013. Crossref
-
Wang Qin, Chen Yongjing, Xie Fang, Ge Yan, Wang Xuefeng, Zhang Xueguang, A Novel Agonist Anti-Human OX40L Monoclonal Antibody That Stimulates T Cell Proliferation and Enhances Cytokine Secretion, Hybridoma, 28, 4, 2009. Crossref
-
Tomei Sara, Wang Ena, Delogu Lucia Gemma, Marincola Francesco M, Bedognetti Davide, Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma, Expert Opinion on Biological Therapy, 14, 5, 2014. Crossref
-
Murphy Judith T., Burey Andre P., Beebe Amy M., Gu Danling, Presta Leonard G., Merghoub Taha, Wolchok Jedd D., Anaphylaxis caused by repetitive doses of a GITR agonist monoclonal antibody in mice, Blood, 123, 14, 2014. Crossref
-
Hirschhorn-Cymerman Daniel, Rizzuto Gabrielle A., Merghoub Taha, Cohen Adam D., Avogadri Francesca, Lesokhin Alexander M., Weinberg Andrew D., Wolchok Jedd D., Houghton Alan N., OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis, Journal of Experimental Medicine, 206, 5, 2009. Crossref
-
Schrama D., Hauschild A., Becker J.C., Immunmodulierende Antikörper in der Dermatoonkologie, Der Hautarzt, 59, 10, 2008. Crossref
-
Chen Mingshui, Ouyang Haichao, Zhou Shangyong, Li Jieyu, Ye Yunbin, PLGA-nanoparticle mediated delivery of anti-OX40 monoclonal antibody enhances anti-tumor cytotoxic T cell responses, Cellular Immunology, 287, 2, 2014. Crossref
-
Redmond William L., Gough Michael J., Weinberg Andrew D., Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo , European Journal of Immunology, 39, 8, 2009. Crossref
-
Chu Haiyan, Hui Gaoyun, Yuan Lin, Shi Danni, Wang Yubang, Du Mulong, Zhong Dongyan, Ma Lan, Tong Na, Qin Chao, Yin Changjun, Zhang Zhengdong, Wang Meilin, Identification of novel piRNAs in bladder cancer, Cancer Letters, 356, 2, 2015. Crossref
-
Buglio Daniela, Mamidipudi Vidya, Khaskhely Noor M., Brady Helen, Heise Carla, Besterman Jeffrey, Martell Robert E., MacBeth Kyle, Younes Anas, The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism, British Journal of Haematology, 151, 4, 2010. Crossref
-
Cuesta Ángel M., Sainz-Pastor Noelia, Bonet Jaume, Oliva Baldomero, Álvarez-Vallina Luis, Multivalent antibodies: when design surpasses evolution, Trends in Biotechnology, 28, 7, 2010. Crossref
-
Sanmamed Miguel F., Pastor Fernando, Rodriguez Alfonso, Perez-Gracia Jose Luis, Rodriguez-Ruiz Maria E., Jure-Kunkel Maria, Melero Ignacio, Agonists of Co-stimulation in Cancer Immunotherapy Directed Against CD137, OX40, GITR, CD27, CD28, and ICOS, Seminars in Oncology, 42, 4, 2015. Crossref
-
Linch Stefanie N., McNamara Michael J., Redmond William L., OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal, Frontiers in Oncology, 5, 2015. Crossref
-
Bell R. Bryan, Leidner Rom S., Crittenden Marka R., Curti Brendan D., Feng Zipei, Montler Ryan, Gough Michael J., Fox Bernard A., Weinberg Andrew D., Urba Walter J., OX40 signaling in head and neck squamous cell carcinoma: Overcoming immunosuppression in the tumor microenvironment, Oral Oncology, 52, 2016. Crossref
-
Weinberg Andrew D., Morris Nicholas P., Kovacsovics-Bankowski Magdalena, Urba Walter J., Curti Brendan D., Science gone translational: the OX40 agonist story, Immunological Reviews, 244, 1, 2011. Crossref
-
Buglio Daniela, Khaskhely Noor M., Voo Kui Shin, Martinez-Valdez Hector, Liu Yong-Jun, Younes Anas, HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma, Blood, 117, 10, 2011. Crossref
-
Park Jong Chul, Hahn Noah M., Emerging role of immunotherapy in urothelial carcinoma—Future directions and novel therapies, Urologic Oncology: Seminars and Original Investigations, 34, 12, 2016. Crossref
-
Redmond William L., Linch Stefanie N., Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8+ T cells, Human Vaccines & Immunotherapeutics, 12, 10, 2016. Crossref
-
Montler Ryan, Bell R Bryan, Thalhofer Colin, Leidner Rom, Feng Zipei, Fox Bernard A, Cheng Allen C, Bui Tuan G, Tucker Christopher, Hoen Helena, Weinberg Andrew, OX40, PD-1 and CTLA-4 are selectively expressed on tumor-infiltrating T cells in head and neck cancer, Clinical & Translational Immunology, 5, 4, 2016. Crossref
-
Maherzi C., Onodi F., Tartour E., Terme M., Tanchot C., Strategies to Reduce Intratumoral Regulatory T Cells, in Oncoimmunology, 2018. Crossref
-
Domingos Patrícia Luciana Batista, Viana Agostinho Gonçalves, Fraga Carlos Alberto de Carvalho, Bonan Paulo Rogério Ferreti, OX40+ T lymphocytes and IFN-γ are associated with American tegumentary leishmaniasis pathogenesis, Anais Brasileiros de Dermatologia, 87, 6, 2012. Crossref
-
Melero Ignacio, Pérez-Ruiz Elisabeth, Sanchez-Paulete Alfonso R., Teijeira Alvaro, Aznar Angela, Sanmamed Miguel F., Co-stimulation Agonists via CD137, OX40, GITR, and CD27 for Immunotherapy of Cancer, in Oncoimmunology, 2018. Crossref
-
Solinas Cinzia, Gombos Andrea, Latifyan Sofiya, Piccart-Gebhart Martine, Kok Marleen, Buisseret Laurence, Targeting immune checkpoints in breast cancer: an update of early results, ESMO Open, 2, 5, 2017. Crossref
-
Pham Minh Ngoc, Murata Satoshi, Kitamura Naomi, Ueki Tomoyuki, Kojima Masatsugu, Miyake Toru, Takebayashi Katsushi, Kodama Hirokazu, Mekata Eiji, Tani Masaji, In vivoantitumor function of tumor antigen-specific CTLs generated in the presence of OX40 co-stimulationin vitro, International Journal of Cancer, 142, 11, 2018. Crossref
-
Weinberg Andrew D., The Role of OX40 (CD134) in T-Cell Memory Generation, in Memory T Cells, 684, 2010. Crossref
-
Qui Harry Z., Hagymasi Adam T., Bandyopadhyay Suman, St. Rose Marie-Clare, Ramanarasimhaiah Raghunath, Ménoret Antoine, Mittler Robert S., Gordon Scott M., Reiner Steven L., Vella Anthony T., Adler Adam J., CD134 Plus CD137 Dual Costimulation Induces Eomesodermin in CD4 T Cells To Program Cytotoxic Th1 Differentiation, The Journal of Immunology, 187, 7, 2011. Crossref
-
Wing James Badger, Tay Christopher, Sakaguchi Shimon, Control of Regulatory T Cells by Co-signal Molecules, in Co-signal Molecules in T Cell Activation, 1189, 2019. Crossref
-
Vieyra-Garcia Pablo, Crouch Jack D., O’Malley John T., Seger Edward W., Yang Chao H., Teague Jessica E., Vromans Anna Maria, Gehad Ahmed, Win Thet Su, Yu Zizi, Lowry Elizabeth L., Na Jung-Im, Rook Alain H., Wolf Peter, Clark Rachael A., Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma, JCI Insight, 4, 1, 2019. Crossref
-
Malamas Anthony S., Hammond Scott A., Schlom Jeffrey, Hodge James W., Combination therapy with an OX40L fusion protein and a vaccine targeting the transcription factor twist inhibits metastasis in a murine model of breast cancer, Oncotarget, 8, 53, 2017. Crossref
-
Lei Wei , Zeng Daxiong , Liu Gaoqin , Zhu Yehan , Wang Jiajia , Wu Hongya , Jiang Junhong , Huang Jianan , Crucial role of OX40/OX40L signaling in a murine model of asthma, Molecular Medicine Reports, 2018. Crossref
-
Amon Lukas, Hatscher Lukas, Heger Lukas, Dudziak Diana, Lehmann Christian H. K., Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy, Pharmaceutics, 12, 7, 2020. Crossref
-
Stachyra Karolina, Dudzisz-Śledź Monika, Bylina Elżbieta, Szumera-Ciećkiewicz Anna, Spałek Mateusz J., Bartnik Ewa, Rutkowski Piotr, Czarnecka Anna M., Merkel Cell Carcinoma from Molecular Pathology to Novel Therapies, International Journal of Molecular Sciences, 22, 12, 2021. Crossref
-
Darwish Martine, Shatz Whitney, Leonard Brandon, Loyet Kelly, Barrett Kathy, Wong Janice L., Li Hong, Abraham Ryan, Lin May, Franke Yvonne, Tam Christine, Mortara Kyle, Zilberleyb Inna, Blanchette Craig, Nanolipoprotein Particles as a Delivery Platform for Fab Based Therapeutics, Bioconjugate Chemistry, 31, 8, 2020. Crossref
-
Kondo Kayo, Okuma Kazu, Tanaka Reiko, Matsuzaki Goro, Ansari Aftab A., Tanaka Yuetsu, Rapid induction of OX40 ligand on primary T cells activated under DNA-damaging conditions, Human Immunology, 69, 9, 2008. Crossref
-
Leyland Rebecca, Watkins Amanda, Mulgrew Kathy A., Holoweckyj Nicholas, Bamber Lisa, Tigue Natalie J., Offer Emily, Andrews John, Yan Li, Mullins Stefanie, Oberst Michael D., Coates Ulrichsen Jane, Leinster David A., McGlinchey Kelly, Young Lesley, Morrow Michelle, Hammond Scott A., Mallinder Philip, Herath Athula, Leow Ching Ching, Wilkinson Robert W., Stewart Ross, A Novel Murine GITR Ligand Fusion Protein Induces Antitumor Activity as a Monotherapy That Is Further Enhanced in Combination with an OX40 Agonist, Clinical Cancer Research, 23, 13, 2017. Crossref
-
Sturgill Elizabeth R., Rolig Annah S., Linch Stefanie N., Mick Courtney, Kasiewicz Melissa J., Sun Zhaoyu, Traber Peter G., Shlevin Harold, Redmond William L., Galectin-3 inhibition with belapectin combined with anti-OX40 therapy reprograms the tumor microenvironment to favor anti-tumor immunity, OncoImmunology, 10, 1, 2021. Crossref
-
Curti Brendan D., Kovacsovics-Bankowski Magdalena, Morris Nicholas, Walker Edwin, Chisholm Lana, Floyd Kevin, Walker Joshua, Gonzalez Iliana, Meeuwsen Tanisha, Fox Bernard A., Moudgil Tarsem, Miller William, Haley Daniel, Coffey Todd, Fisher Brenda, Delanty-Miller Laurie, Rymarchyk Nicole, Kelly Tracy, Crocenzi Todd, Bernstein Eric, Sanborn Rachel, Urba Walter J., Weinberg Andrew D., OX40 Is a Potent Immune-Stimulating Target in Late-Stage Cancer Patients, Cancer Research, 73, 24, 2013. Crossref